Saxenda vs Victoza: The Two Faces of Liraglutide

Same molecule, different doses

Liraglutide is a once-daily GLP-1 receptor agonist, approved by the FDA in 2010. From the start, Novo Nordisk developed it for two indications — type 2 diabetes and obesity — and chose to sell each indication under a different brand name. Victoza is the diabetes formulation; Saxenda is the obesity formulation. The molecule is identical. The doses and indications are different.

• Victoza: liraglutide, approved at up to 1.8 mg once daily for type 2 diabetes. Some patients use 0.6 mg or 1.2 mg as their maintenance dose if 1.8 mg is not tolerated or not needed.
• Saxenda: liraglutide, approved at 3.0 mg once daily for chronic weight management. Titration is 0.6 -> 1.2 -> 1.8 -> 2.4 -> 3.0 mg over five weeks.

Saxenda is essentially Victoza pushed to a higher dose, with separate FDA approval for the obesity indication. The chemistry is unchanged. The difference is which condition the drug is being used to treat — and that determines which insurance pathway covers it.

Approved indications: when each is prescribed

Victoza is FDA-approved for:

• Type 2 diabetes — as an adjunct to diet and exercise to improve glycemic control.
• Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (added 2017 based on the LEADER trial).

Saxenda is FDA-approved for:

• Chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity.
• Adolescents aged 12-17 with obesity (added 2020) — this was the first GLP-1 drug approved for pediatric obesity, and Saxenda's adolescent indication remains a niche where it has unique standing.

A patient with type 2 diabetes who also has obesity will typically be prescribed Victoza (the diabetes pathway is the primary indication, and insurance follows). A patient with obesity but no diabetes will typically be prescribed Saxenda.

Why the brand split exists

The two-brand approach is largely regulatory and commercial:

Regulatory: each indication requires its own FDA approval with its own trial program, label, and dose. Saxenda's 3.0 mg dose for obesity required a separate Phase 3 program (SCALE) to demonstrate efficacy and safety at that higher dose — and the result was its own NDA, its own label, and its own brand identity.

Commercial: separate brands allow separate marketing, separate sales force focus, and separate negotiation with insurance plans. The diabetes market and the obesity market are reimbursed very differently — diabetes is broadly covered, while obesity coverage has been patchier — and a single brand name would have complicated both pricing and access.

This pattern is not unique to liraglutide. Semaglutide is the same molecule sold as Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral diabetes). Tirzepatide is sold as Mounjaro (diabetes) and Zepbound (obesity). The brand-split-by-indication is now standard in the GLP-1 class.

Where liraglutide still has niches

Semaglutide and tirzepatide have largely displaced liraglutide for new starts since 2017-2022. Both produce deeper weight loss with less-frequent dosing (weekly vs daily). But liraglutide retains a few specific positions:

• Adolescent obesity — Saxenda is FDA-approved for ages 12-17; Wegovy's adolescent approval came later (2022). For some patients and providers, the longer real-world record matters.
• Established LEADER cardiovascular evidence — Victoza's cardiovascular outcomes data is older than semaglutide's SELECT trial, but it is robust and well-established.
• Daily-dose tolerability — some patients tolerate a daily lower-exposure GLP-1 better than a weekly higher-exposure one. The "less drug, more often" profile of liraglutide is a real niche for sensitive patients.
• Patients who failed semaglutide tolerability — switching down to liraglutide (with daily dosing and lower exposure) sometimes works when weekly drugs do not.

Practical implications

Insurance and coverage are the biggest practical difference between Victoza and Saxenda. A patient prescribed Victoza for diabetes typically has broad coverage; the same patient switched to Saxenda for obesity will often hit a higher prior-authorization wall, different formulary tier, and a separate manufacturer coupon program. Switching between them mid-treatment is a process — not a substitution at the pharmacy.

Switching between them requires a new prescription, a new prior authorization, and possibly re-titration if the dose ranges differ. A patient maintained on Victoza 1.8 mg who switches to Saxenda generally continues at 1.8 mg and then titrates up to 3.0 mg over a few additional weeks.

Dosing is once daily for both — at the same time each day, with or without food. The daily injection is the main practical limitation versus weekly semaglutide or tirzepatide.

The honest read

Saxenda and Victoza are the same drug at different doses, sold under different names for regulatory and commercial reasons that have nothing to do with chemistry. Both have been largely displaced in new prescribing by semaglutide and tirzepatide, but both retain specific niches — pediatric obesity for Saxenda, established cardiovascular evidence for Victoza, and daily-dose tolerability for both. Knowing that they are the same molecule clarifies a lot of the confusion in patient discussions: switching between them is a brand and indication change, not a drug change, and the underlying liraglutide pharmacology is identical.